Absci: Creating Drugs at the Speed of AI
NASDAQ: ABSI | Absci Website
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster.
Most drug discovery approaches today look to existing antibody libraries for incremental improvements; however, Absci designs antibodies “from scratch” on a computer, generating candidates unlike those found in existing databases. Their wet lab can then experimentally validate the candidates that work right out of the computer, potentially reducing the time it takes to get new drug leads into the clinic while unlocking treatments for traditionally “undruggable” diseases and improved therapeutic possibilities for many others.
In this interview with Yolande Lougheed, Absci CEO Sean McClain discusses the company’s collaboration with leading researchers at the California Institute of Technology (Caltech) in a joint effort to discover affordable HIV therapeutic vaccinations, with the goal of making a significant step forward in the fight against the global HIV/AIDS epidemic.
Absci is a Corporate Marketing Partner of IDG. IDG’s Corporate Marketing Programs are for world-class growth companies interested in driving awareness within high value alternative capital channels including family offices. Throughout the year-long program, IDG sets the stage for you to share your story with in-person presentations, video interviews, virtual events, and a comprehensive marketing program.
To learn more about IDG’s Corporate Marketing Program, please contact Steve Davidson.